Cholestin controversy may encourage challenges of other source botanicals -- AHPA.
This article was originally published in The Tan Sheet
Executive Summary
CHOLESTIN CONTROVERSY MAY ENCOURAGE CHALLENGES OF OTHER BOTANICALS containing small amounts of old or new drug ingredients, the American Herbal Products Association suggests in Jan. 30 comments to FDA. "AHPA is concerned that the present controversy could create incentives for those who develop new drugs from botanicals to attack the regulatory status of the source botanical once the pharmaceutical grade new drug has been approved," the association states. FDA has suggested to marketer Pharmanex that Cholestin's lovastatin content renders the product an unapproved new drug.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning